ATE530070T1 - Verwendung von lactobacillus casei zur verstärkung der schutzwirkung der grippeimpfung - Google Patents

Verwendung von lactobacillus casei zur verstärkung der schutzwirkung der grippeimpfung

Info

Publication number
ATE530070T1
ATE530070T1 AT08775550T AT08775550T ATE530070T1 AT E530070 T1 ATE530070 T1 AT E530070T1 AT 08775550 T AT08775550 T AT 08775550T AT 08775550 T AT08775550 T AT 08775550T AT E530070 T1 ATE530070 T1 AT E530070T1
Authority
AT
Austria
Prior art keywords
strengthen
protective effect
lactobacillus casei
flu vaccine
flu
Prior art date
Application number
AT08775550T
Other languages
English (en)
Inventor
Sandrine Samson-Villeger
Raphaelle Bourdet-Sicard
Original Assignee
Gervais Danone Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gervais Danone Sa filed Critical Gervais Danone Sa
Application granted granted Critical
Publication of ATE530070T1 publication Critical patent/ATE530070T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A23C9/1234—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt characterised by using a Lactobacillus sp. other than Lactobacillus Bulgaricus, including Bificlobacterium sp.
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; PREPARATION THEREOF
    • A23C9/00—Milk preparations; Milk powder or milk powder preparations
    • A23C9/12—Fermented milk preparations; Treatment using microorganisms or enzymes
    • A23C9/123—Fermented milk preparations; Treatment using microorganisms or enzymes using only microorganisms of the genus lactobacteriaceae; Yoghurt
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/125—Casei

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
AT08775550T 2007-02-16 2008-02-13 Verwendung von lactobacillus casei zur verstärkung der schutzwirkung der grippeimpfung ATE530070T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0701140A FR2912657B1 (fr) 2007-02-16 2007-02-16 Utilisation de lactobacillus casei pour renforcer la protection induite par la vaccination anti-grippale.
PCT/FR2008/000181 WO2008129148A2 (fr) 2007-02-16 2008-02-13 Utilisation de lactobacillus casei pour renforcer la protection induite par la vaccination anti-grippale

Publications (1)

Publication Number Publication Date
ATE530070T1 true ATE530070T1 (de) 2011-11-15

Family

ID=38508753

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08775550T ATE530070T1 (de) 2007-02-16 2008-02-13 Verwendung von lactobacillus casei zur verstärkung der schutzwirkung der grippeimpfung

Country Status (16)

Country Link
US (1) US8349315B2 (de)
EP (1) EP2120590B1 (de)
JP (1) JP2010518151A (de)
KR (1) KR20090115960A (de)
CN (1) CN101918013A (de)
AR (1) AR065362A1 (de)
AT (1) ATE530070T1 (de)
BR (1) BRPI0807649A2 (de)
CA (1) CA2678004A1 (de)
ES (1) ES2378052T3 (de)
FR (1) FR2912657B1 (de)
MX (1) MX2009008767A (de)
PL (1) PL2120590T3 (de)
RU (1) RU2470994C2 (de)
WO (1) WO2008129148A2 (de)
ZA (1) ZA200905551B (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2937252B1 (fr) 2008-10-17 2011-05-20 Pf Medicament Association d'un extrait de sureau et d'une souche de l. paracasei.
CN103220921B (zh) * 2010-10-15 2015-12-16 科.汉森有限公司 免疫佐剂
WO2014038929A1 (en) 2012-09-07 2014-03-13 N.V. Nutricia Probiotics for producing antiviral factors
SG10201810886YA (en) * 2013-08-26 2019-01-30 Meiji Co Ltd Antibody titer-increasing agent using lactic acid bacterium
WO2018220416A1 (en) * 2017-05-31 2018-12-06 Compagnie Gervais Danone Lactobacillus paracasei strain capable of improving the immune response to a viral-bacterial coinfection
US20240408154A1 (en) * 2021-11-02 2024-12-12 Kabushiki Kaisha Yakult Honsha Enhancer of number of tcr clones

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1289984B1 (it) * 1997-02-27 1998-10-19 Proge Farm Srl Ceppi di lattobacilli utili nel trattamento di disfunzioni del sistema gastrointestinale
FR2809312B1 (fr) * 2000-05-25 2002-07-12 Gervais Danone Sa Utilisation de l. casei dans des compositions immunostimulantes
WO2006124630A2 (en) * 2005-05-13 2006-11-23 New England Medical Center Hospitals, Inc. Compositions and methods for enhancing the efficacy of vaccines

Also Published As

Publication number Publication date
JP2010518151A (ja) 2010-05-27
US8349315B2 (en) 2013-01-08
EP2120590A2 (de) 2009-11-25
KR20090115960A (ko) 2009-11-10
US20100129334A1 (en) 2010-05-27
CA2678004A1 (fr) 2008-10-30
ZA200905551B (en) 2010-05-26
RU2470994C2 (ru) 2012-12-27
BRPI0807649A2 (pt) 2014-06-10
PL2120590T3 (pl) 2012-05-31
WO2008129148A3 (fr) 2009-02-12
EP2120590B1 (de) 2011-10-26
ES2378052T3 (es) 2012-04-04
FR2912657B1 (fr) 2009-04-17
AR065362A1 (es) 2009-06-03
MX2009008767A (es) 2009-10-12
CN101918013A (zh) 2010-12-15
FR2912657A1 (fr) 2008-08-22
WO2008129148A2 (fr) 2008-10-30
RU2009134520A (ru) 2011-03-27

Similar Documents

Publication Publication Date Title
IL269427B (en) Vaccine nanotechnology
EP2640853A4 (de) Modulation von alpha-synukleinexpression
EP2553522A4 (de) Elektrophoretische medien
EP2306823A4 (de) Formulierungen von 5-fluorcytosin und ihre verwendungen
SMT201500140B (it) Composizione per inibire l'espressione genica e suoi usi
FI20095529A0 (fi) Probioottien uusi käyttö
EP2217064A4 (de) Neue impfstoffe gegen mehrere subtypen des influenzavirus
EP2219653A4 (de) Mikro-rnas der mir-15-familie zur modulierung des kardiomyozyten-überlebens und herzreparatur
HRP20160737T1 (hr) Anti-her3-protutijela i njihove uporabe
IL225607A0 (en) Heteroaryls and uses thereof
EP2393914A4 (de) Lungengewebekonstruktion
EP2509991A4 (de) Modulation der hsp47-expression
HRP20180718T1 (hr) Oligopeptidni spojevi i njihova upotreba
LT2605789T (lt) Modifikuoti relaksino polipeptidai ir jų panaudojimas
EP2432599A4 (de) System zur zerstörung von festplatten
EP2547373A4 (de) Nanoröhren und zusammensetzung davon
EP2644650A4 (de) Kautschukzusammensetzung und reifen damit
EP2539439A4 (de) Angiogenese-modulation
EP2433996A4 (de) Haftzusammensetzung und endoskop
FR2938552B1 (fr) Souche hypocholesterolemiante de lactobacillus delbrueckii
ITVE20080083A1 (it) Tasselli ad incastri per realizzare oggetti e/o giocattoli
EP2474315A4 (de) Immunitätsinduzierer
DE11786796T8 (de) Antigenpeptid und verwendung davon
BRPI0921730A2 (pt) Compisição para ativar e/ou estabilizar micro-organismos
BRPI0807649A2 (pt) Utilização de lactobacillus casei para reforçar a proteção induzida pela vacina antigripal

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties